New Delhi, Jan 16, 2015: Piramal Enterprises’ Pharma Solution division, a global leader in contract development and manufacturing (CDMO), was a big winner in the recent CMO Leadership Awards held in Boston, USA, securingfour awards in three key categories:Quality, Reliability, & Regulatory. Respondents from Big Pharma, Mid-sized and Specialty Pharma, and Emerging Pharma, voted Piramal to be amongst the top 10% in these categories.
The CMO Leadership Awards by Life Science Leader magazine is based on industry leading research conducted by Nice Insight. Nice insights surveys over 11,000 industry executives- buyers of outsourced services annually, to determine perception and awareness scores of CMOs for five different attributes (i.e. Innovation, Productivity, Quality, Regulatory, and Reliability).The four categories in which the Pharma Solution division has won are:
§ Reliability for Big Pharma
§ Reliability for Mid-Size & Specialty Pharma
§ Regulatory for Mid-Size & Specialty Pharma
§ Quality for Emerging Pharma
Companies achieving top 20 percentile perception scores across these 5 attributes are recognized for their achievement.
For 2015, the research respondents were broken in to 5 categories: Big Pharma (BP), Mid-Size & Specialty Pharma (MP), Emerging Pharma (EP), Biotech (BT) and Emerging Biotech (EBT). The top 10% in each of these above categories were chosen as winners of CMO leadership awards. Unlike other industry awards, which are given based on a subjective voting or nomination process, the only votes that count towards the CRO/CMO Leadership Awards are those of the pharmaceutical and biopharmaceutical companies using CRO/CMO services.The research respondents of all categories voted Piramal Enterprises’Pharma Solution division to be amongst the top 10% in these categories.
Mr.Vivek Sharma, CEO – PiramalPharma Solutions said, “We are delightedto receive this prestigious award and to be recognized in multiple areas and categories. Theaward serves as a validationof oureffortsto keep the customer as the focal point, while emphasizing on project ownership, time delivery and commitment towards quality. This recognition from our clientswillfurther motivateour team as we drive towards becoming the ‘partner of choice’. Receiving these awards also showcase our company values of entrepreneurship, expertise and trusteeship.”
PiramalPharma Solutions is known for its capabilities as an integrated solutions provider offering comprehensive range of services across the drug lifecycle. With a successful performance record of over four decadesin API supply, Drug Products, and Drug Discovery services, and with supply facilities in North America, Europe, and Asia; it has established itself as a global market leader.
To serve its partners better, PiramalPharma Solutions continuesto invest in next generation technologies and R&D: recent investments include areas such as Anti-Body Drug Conjugation (ADC), BiocatalysisCenter of Excellence, and Advanced Flow Reactor(AFR) systems.In addition to investing$40Min new equipment and technologies, theyare also augmenting related infrastructure. Recently the companycompleted a green field facility ($10M) to double its Discovery Services capacity, and also approved a $20M capacity expansion for Hormonal (Morpeth)and ADC (Grangemouth) manufacturing.CCI Newswire
